Regeneron Pharmaceuticals (REGN) net income: $4.5B
Regeneron Pharmaceuticals reported a net income of $4.5B for the year ended Dec 31, 2025, up 2.1% from $4.4B a year earlier.
From Regeneron Pharmaceuticals's filings with the SEC · Read the filing · REGN stock page
Regeneron Pharmaceuticals net income by year
#98 of 3,748 US companies by net income · See the full ranking
| Year ended | Net income | Change |
|---|---|---|
| Dec 31, 2025 | $4.5B | +2% |
| Dec 31, 2024 | $4.4B | +12% |
| Dec 31, 2023 | $4B | -9% |
| Dec 31, 2022 | $4.3B | -46% |
| Dec 31, 2021 | $8.1B | – |
Net income of similar companies
Companies in the same industry as Regeneron Pharmaceuticals, by SEC industry code, with the closest net income. Each name opens the same page for that company.
| Company | Net income, latest year | Year ended |
|---|---|---|
| Pfizer | $7.8B | Dec 31, 2025 |
| Bristol Myers Squibb | $7.1B | Dec 31, 2025 |
| Abbott Laboratories | $6.5B | Dec 31, 2025 |
| Regeneron Pharmaceuticals | $4.5B | Dec 31, 2025 |
| AbbVie | $4.2B | Dec 31, 2025 |
| Vertex Pharmaceuticals Inc / Ma | $4B | Dec 31, 2025 |
| Zoetis | $2.7B | Dec 31, 2025 |
Questions and answers
What is Regeneron Pharmaceuticals's net income?
Regeneron Pharmaceuticals reported a net income of $4.5B for the year ended Dec 31, 2025, up 2.1% from $4.4B a year earlier.
Numbers as reported in Regeneron Pharmaceuticals's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology